Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Journal of Gastrointestinal Cancer
Erschienen in: Journal of Gastrointestinal Cancer 3/2017

23.06.2017 | Review Article

Cancer Stem Cells in Hepatocellular Carcinoma

verfasst von: Tamer Yagci, Metin Cetin, Pelin Balcik Ercin

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepatocellular carcinoma is one of the most common cancers and the second leading cause of cancer-related deaths worldwide. Only a small proportion of patients benefit from curative treatment and the prognosis is very poor for the majority of cases due to late presentation, resistance to chemotherapy and high recurrence rate. In recent years, progress in stem cell biology allowed us to explain that hierarchically organized cancer stem cells (CSCs) drive histological and functional heterogeneity of hematological malignancies and solid tumors.

Methods and Results

Also referred to as tumor-initiating cells, CSCs have been isolated from both hepatocellular carcinoma (HCC) cell lines and primary tumors by using hepatic progenitor markers. Although there is still no consensus on cancer stem cell phenotype in HCC, single or combined use of CSC markers defines a minor population of tumor cells with the capacity of self-renewing and the ability to recapitulate the original tumor heterogeneity.

Conclusions

This review focuses on the biological features of CSCs and their potential as diagnostic/prognostic tools and therapeutic targets in HCC.
Literatur
1.
Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–8.CrossRef
2.
Reya T, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11.CrossRef
3.
Soltysova A, Altanerova V, Altaner C. Cancer stem cells. Neoplasma. 2005;52(6):435.
4.
Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10(6):717–28.CrossRef
5.
Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977;197(4302):461–3.CrossRef
6.
Dick D. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature med. 1997;3(730–737):1.
7.
Al-Hajj M, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci. 2003;100(7):3983–8.CrossRef
8.
Dalerba P, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci. 2007;104(24):10158–63.CrossRef
9.
O’Brien CA, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–10.CrossRef
10.
Ricci-Vitiani L, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.CrossRef
11.
Li C, et al. Identification of pancreatic cancer stem cells. Cancer res. 2007;67(3):1030–7.CrossRef
12.
Singh SK, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.CrossRef
13.
Bao S, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–60.CrossRef
14.
Piccirillo S, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444(7120):761–5.CrossRef
15.
Chiba T, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties. Hepatology. 2006;44(1):240–51.CrossRef
16.
Haraguchi N, et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 2006;24(3):506–13.CrossRef
17.
Yang ZF, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13(2):153–66.CrossRef
18.
Zhang S, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer res. 2008;68(11):4311–20.PubMedCentralCrossRef
19.
Curley MD, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009;27(12):2875–83.
20.
Sugihara E, Saya H. Complexity of cancer stem cells. Int J Cancer. 2013;132(6):1249–59.CrossRef
21.
Clevers H. The cancer stem cell: premises, promises and challenges. Nat med. 2011:313–9.CrossRef
22.
Zhou B-BS, et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat rev Drug Discov. 2009;8(10):806–23.CrossRef
23.
Patel P, Chen E. Cancer stem cells, tumor dormancy, and metastasis. Front Endocrinol. 2012;3:125.CrossRef
24.
Mani SA, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.PubMedCentralCrossRef
25.
Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741–51.PubMedCentralCrossRef
26.
Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef
27.
London W, McGlynn K. Liver cancer. Cancer Epidemiology and Prevention. 2006;3:763–86.CrossRef
28.
Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRef
29.
Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma. J Gastroenterol Hepatol. 2010;25(9):1485–92.CrossRef
30.
Ma S, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132(7):2542–56.CrossRef
31.
Suetsugu A, et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys res Commun. 2006;351(4):820–4.CrossRef
32.
Yamashita T, et al. Activation of hepatic stem cell marker EpCAM by Wnt–β-catenin signaling in hepatocellular carcinoma. Cancer res. 2007;67(22):10831–9.CrossRef
33.
34.
Zhang L, et al. The stem cell niche of human livers: symmetry between development and regeneration. Hepatology. 2008;48(5):1598–607.CrossRef
35.
Tang Y, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling. Proc Natl Acad Sci. 2008;105(7):2445–50.CrossRef
36.
Chen Y, et al. Mature hepatocytes exhibit unexpected plasticity by direct dedifferentiation into liver progenitor cells in culture. Hepatology. 2012;55(2):563–74.PubMedCentralCrossRef
37.
Yin S, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120(7):1444–50.CrossRef
38.
Yang ZF, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008;47(3):919–28.CrossRef
39.
Yamashita T, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–1024. e4.CrossRef
40.
41.
Yin AH, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90(12):5002–12.
42.
Grosse-Gehling P, et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol. 2013;229(3):355–78.CrossRef
43.
Zheng Y-W, et al. The CD133+ CD44+ precancerous subpopulation of oval cells is a therapeutic target for hepatocellular carcinoma. Stem Cells dev. 2014;23(18):2237–49.PubMedCentralCrossRef
44.
Tang KH, et al. CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology. 2012;55(3):807–20.CrossRef
45.
Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35(3):211–31.CrossRef
46.
Afify A, Purnell P, Nguyen L. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol. 2009;86(2):95–100.CrossRef
47.
van der Windt GJ, et al. CD44 is protective during hyperoxia-induced lung injury. Am J Respir Cell Mol Biol. 2011;44(3):377–83.CrossRef
48.
Zhu Z, et al. Cancer stem/progenitor cells are highly enriched in CD133+ CD44+ population in hepatocellular carcinoma. Int J Cancer. 2010;126(9):2067–78.
49.
Reif AE, Allen JM. The AKR thymic antigen and its distribution in leukemias and nervous tissues. J Exp med. 1964;120(3):413–33.PubMedCentralCrossRef
50.
Mima K, et al. CD44s regulates the TGF-β–mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer res. 2012;72(13):3414–23.CrossRef
51.
Ishimoto T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc− and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387–400.CrossRef
52.
Lu J-W, et al. Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. Acta Histochem. 2011;113(8):833–8.CrossRef
53.
Went PT, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35(1):122–8.CrossRef
54.
Kim JW, et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology. 2004;39(2):518–27.CrossRef
55.
Yamashita T, et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology. 2013;57(4):1484–97.CrossRef
56.
Kurtz J-E, Dufour P. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010;10(6):951–8.CrossRef
57.
Gires O, Bauerle PA. EpCAM as a target in cancer therapy. J Clin Oncol. 2010;28(15):e239–40.CrossRef
58.
Mina-Osorio P. The moonlighting enzyme CD13: old and new functions to target. Trends Mol med. 2008;14(8):361–71.CrossRef
59.
Kim HM, et al. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial–mesenchymal transition-like phenomenon. Ann Surg Oncol. 2012;19(3):539–48.CrossRef
Metadaten
Titel
Cancer Stem Cells in Hepatocellular Carcinoma
verfasst von
Tamer Yagci
Metin Cetin
Pelin Balcik Ercin
Publikationsdatum
23.06.2017
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 3/2017
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-017-9960-7

Weitere Artikel der Ausgabe 3/2017

Journal of Gastrointestinal Cancer 3/2017 Zur Ausgabe

Review Article

Radiological Response to the Locoregional Treatment in Hepatocellular Carcinoma: RECIST, mRECIST, and Others

Abstract

Yttrium-90 (Y-90) Resin Microsphere Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Single-Center Experience

Review Article

Barcelona Clinic Liver Cancer (BCLC) Staging: Does It Cover All Our Expectation

Review Article

Surveillance of the Patients with High Risk of Hepatocellular Cancer

Review Article

Hepatocellular Cancer: Is Recurrence Inevitable?

Review Article

Angiogenesis, Invasion, and Metastasis Characteristics of Hepatocellular Carcinoma

Neu im Fachgebiet Onkologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise